GBIO NASDAQ
Generation Bio Co.
1W: +3.8%
1M: +12.5%
3M: -5.8%
1Y: -46.9%
3Y: -86.5%
5Y: -98.4%
$5.34
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$36.0M
52W Range3.004-7.516
Volume551,924
Avg Volume82,006
Beta2.01
Dividend—
Analyst Ratings
Company Info
CEOYalonda Howze
Employees115
SectorHealthcare
IndustryBiotechnology
IPO Date2020-06-12
Websitegenerationbio.com
301 Binney Street
Cambridge, MA 02142
US
Cambridge, MA 02142
US
617 655 7500
About Generation Bio Co.
Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.
Latest News
Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages
Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25
Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders
GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Atlas Venture Fund X | U-Tender | 60 | $0.00 | 2026-02-09 |
| Stehman-Breen Cather | D-Return | 6,000 | $33.20 | 2026-02-09 |
| Stehman-Breen Cather | D-Return | 3,000 | $3.87 | 2026-02-09 |
| Stehman-Breen Cather | D-Return | 5,200 | $190.00 | 2026-02-09 |
| Stehman-Breen Cather | D-Return | 1,500 | $265.90 | 2026-02-09 |